Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 1
2007 1
2008 4
2009 1
2010 3
2011 3
2012 2
2013 4
2014 2
2016 2
2017 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
How current understanding of clearance mechanisms and pharmacodynamics of therapeutic proteins can be applied for evaluation of their drug-drug interaction potential.
Kraynov E, Martin SW, Hurst S, Fahmi OA, Dowty M, Cronenberger C, Loi CM, Kuang B, Fields O, Fountain S, Awwad M, Wang D. Kraynov E, et al. Among authors: fahmi oa. Drug Metab Dispos. 2011 Oct;39(10):1779-83. doi: 10.1124/dmd.111.040808. Epub 2011 Jul 18. Drug Metab Dispos. 2011. PMID: 21768274 Review.
Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper.
Evers R, Dallas S, Dickmann LJ, Fahmi OA, Kenny JR, Kraynov E, Nguyen T, Patel AH, Slatter JG, Zhang L. Evers R, et al. Among authors: fahmi oa. Drug Metab Dispos. 2013 Sep;41(9):1598-609. doi: 10.1124/dmd.113.052225. Epub 2013 Jun 21. Drug Metab Dispos. 2013. PMID: 23792813 Review.
Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome.
Dong JQ, Gosset JR, Fahmi OA, Lin Z, Chabot JR, Terra SG, Le V, Chidsey K, Nouri P, Kim A, Buckbinder L, Kalgutkar AS. Dong JQ, et al. Among authors: fahmi oa. Drug Metab Dispos. 2017 May;45(5):501-511. doi: 10.1124/dmd.116.074476. Epub 2017 Mar 2. Drug Metab Dispos. 2017. PMID: 28254951
Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control.
Hariparsad N, Ramsden D, Palamanda J, Dekeyser JG, Fahmi OA, Kenny JR, Einolf H, Mohutsky M, Pardon M, Siu YA, Chen L, Sinz M, Jones B, Walsky R, Dallas S, Balani SK, Zhang G, Buckley D, Tweedie D. Hariparsad N, et al. Among authors: fahmi oa. Drug Metab Dispos. 2017 Oct;45(10):1049-1059. doi: 10.1124/dmd.116.074567. Epub 2017 Jun 23. Drug Metab Dispos. 2017. PMID: 28646080
25 results